Utility of central venous-arterial pCO2 difference as a prognostic marker for clinical outcomes in Transcatheter Aortic Valve Implantation (TAVI)

Utility of central venous-arterial pCO2 difference as a prognostic marker for clinical outcomes in Transcatheter Aortic Valve Implantation (TAVI) - Central venous-arterial pCO2 difference in a TAVI intervention

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033047

Enrollment

Registered

2024-06-27

Start date

2024-06-21

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ranscatheter Aortic Valve Implantation, I35.0: Aortenklappenstenose, OPS-Code 5-35a.01 OPS: 5-35a.01 I35.0

Interventions

Group 1: In the context of aortic valve stenosis and transcatheter aortic valve implantation (TAVI), the CO2 difference, to our knowledge, has not been investigated as a prognostic marker. Through a s

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: TAVI procedure due to aortic valve stenosis Indwelling intra-arterial catheter in place (obligatory) Superior vena cava catheter (internal jugular or subclavian) in place (obligatory).

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
28 days mortality	—

Secondary

Measure	Time frame
length of hospital and ICU stay, dosage of vasopressors, complications (invasive mechanical ventilation during ICU stay, death at ICU, left heart failure)	—

Countries

Germany

Contacts

Public ContactGereon Schälte

Uniklinikum Aachen

gschaelte@ukaachen.de0049241 – 8088179

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026